Oct 15 2026 10:08 PM EST
Evolent Health Raises Guidance After Strong Q2 Results, Shares Jump
Evolent Health (NYSE: EVH) shares climbed 19.4% over the past five days, reaching $4.87 on Oct 15, after the company released Q2 2026 results that beat revenue expectations and raised its full‑year outlook.
The quarter delivered revenue of $652.5 million, a 46.8% increase year‑over‑year, while the net loss narrowed to $28.4 million (loss margin ‑4.3% versus ‑11.5% a year earlier). Adjusted EBITDA rose to $28.1 million with a 4.3% margin. Management raised FY 2026 revenue guidance to $2.6‑$2.7 billion and tightened adjusted EBITDA guidance to $120‑$135 million. The outlook for FY 2027 projects revenue growth of >25% and an adjusted EBITDA midpoint of at least $150 million.
Q2 Results Lift Guidance
Revenue beat the Zacks consensus by roughly 6.7%, and the adjusted EBITDA margin, though lower than the prior year, improved sequentially from Q1 2026. The company also reported a medical expense ratio (MER) of 95.3%, with expectations to improve toward the FY 2026 target of ~93% as reserves mature.
Contract Wins Expand Revenue Base
Management highlighted several new agreements signed in Q2 2026, including a Highmark Performance Suite launch that contributed two months of revenue to the quarter, an Oncology Performance Suite partnership expected to generate approximately $300 million in annualized revenue, and an imaging contract covering roughly 4.5 million lives. These contracts add to four new revenue agreements announced year‑to‑date, reinforcing the growth narrative.
Analyst Upgrades Bolster Outlook
Following the earnings release, several research firms upgraded their ratings. Citigroup, TD Cowen and JPMorgan each raised their price targets to $6.00, while Canaccord Genuity lifted its target to $7.00. The consensus 12‑month price target now ranges from $5.96 to $6.86, supporting a valuation premium to the current price.
Risks and Uncertainties
The outlook remains subject to several headwinds. Medicaid enrollment is expected to decline by 4‑5% as work‑requirement reforms take effect, potentially offsetting some growth from the Performance Suite pipeline. Specialty‑Tech & Services revenue is projected to be flat or slightly down in 2027. Additionally, the company is navigating a DOJ civil investigative demand covering activities through 2016, and a pending CFO transition could affect execution. Short interest, while down from prior periods, still represents roughly 12% of float, indicating continued market scrutiny.